GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Journal of Clinical Investigation · 03.11.2025 · 135 (21)
DOI: 10.1172/jci194743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.11.2025. Verfasst von Estefania Valencia-Rincón und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Medicine, and. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neoplasms, Translational Research, Biomedical, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer diagnoses are prevalent in people with obesity and type 2 diabetes, and abundant clinical evidence supports the protective effects of weight loss for cancer prevention. Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized obesity and type 2 diabetes medicine and alleviate many comorbidities of these metabolic diseases. In this Review, we summarize the current clinical evidence for GLP-1 receptor agonists and cancer risk, including thyroid, pancreatic, gastrointestinal, and hormone-dependent malignancies. With few exceptions, recent meta-analyses report that GLP-1 receptor therapies do not increase cancer incidence and may lower risk in some cases. Preclinical studies reinforce the anticancer effects of GLP-1 receptor therapies, even in non-obese models. However, there are still many opportunities for translational insight as the field grows. Immune-modulating effects of GLP-1 receptor agonists are reported in several preclinical cancer studies, which may reflect direct action on immune cells or result from improved metabolic function. We highlight ongoing clinical trials for GLP-1 receptor therapies in cancer patients, and offer considerations for preclinical studies, including perspectives on the timing and duration of GLP-1 receptor agonist treatment, concurrent use of standard anticancer therapies, and interpretation of models of cancer risk versus progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, College of Medicine, and.
- Gynecologic Oncology Section, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
- Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
Zitieren
APA
Valencia-Rincón, E., Rai, R., Chandra, V., & Wellberg, E. A. (2025). GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. Journal of Clinical Investigation, 135(21). https://doi.org/10.1172/jci194743
Vancouver
Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. Journal of Clinical Investigation. 2025;135(21). doi:10.1172/jci194743
BibTeX
@article{ValenciaRincn2025,
author = {Valencia-Rincón, Estefania and Rai, Rajani and Chandra, Vishal and Wellberg, Elizabeth A},
title = {GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {21},
doi = {10.1172/jci194743}
}
EUVIMED